Abstract
Survival profiles for immunotherapies such as nivolumab may exhibit a plateau or a delayed effect, leading to complex long-term hazard functions. We aimed to retrospectively analyze the accuracy of overall survival (OS) extrapolations of interim data cuts in predicting realized long-term life years (LYs), to ascertain whether certain survival models might better predict long-term survival with nivolumab across indications.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
